Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Wyckoff

Pulmonary Disease Falls Church, VA Medical Doctor

NPI 1669649620 CMS profile 29839

500 W Annandale Rd, Falls Church, VA 22046

Open in the dashboard

General payments

$9,726

367 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Wyckoff of Falls Church, VA is reported in the CMS Open Payments database as having received $9,726 across 367 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,004 49
2024 General $2,003 87
2023 General $1,624 70
2022 General $1,028 52
2021 General $553 31
2020 General $488 27
2019 General $1,026 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Wyckoff
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Christopher Wyckoff were reported at $3,004. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Christopher Wyckoff Pulmonary Disease median Middle half National median
2019 $1,026 $377 $109–$1,340 $163
2020 $488 $230 $56–$907 $114
2021 $553 $269 $68–$1,072 $132
2022 $1,028 $390 $100–$1,457 $149
2023 $1,624 $419 $114–$1,659 $160
2024 $2,003 $476 $123–$1,818 $164
2025 $3,004 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $3,118 72 payments
  2. AstraZeneca Pharmaceuticals LP $1,666 78 payments
  3. Genzyme Corporation $716 36 payments
  4. Amgen Inc. $473 24 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $431 19 payments
  6. Grifols USA, LLC $372 11 payments
  7. Insmed, Inc. $285 12 payments
  8. Mylan Specialty L.P. $275 12 payments
  9. Electromed, Inc. $233 14 payments
  10. United Therapeutics Corporation $233 9 payments
  11. Other $1,924 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,643 361 payments
  2. Consulting Fee $1,950 1 payment
  3. Education $134 5 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $814 37 payments
  2. BREZTRI $640 21 payments
  3. TRELEGY ELLIPTA $590 39 payments
  4. FASENRA $588 25 payments
  5. TEZSPIRE Inflammation $473 24 payments
  6. NUCALA $413 22 payments
  7. Prolastin-C Liquid $372 11 payments
  8. TEZSPIRE Respiratory $338 16 payments
  9. Arikayce $285 12 payments
  10. OFEV $264 12 payments
  11. Other $3,963 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,534

Median for Critical Care (Intensivists): 406

Drug cost

$1,860,011

Median for Critical Care (Intensivists): $197,260

Branded share of claims

73.5%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 45 $659,288
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 241 $299,852
Opsumit Macitentan Brand 24 $297,869
Zemaira Alpha-1-Proteinase Inhibitor Brand 12 $105,325
Prolastin C Alpha-1-Proteinase Inhibitor Brand 13 $88,023
Breo Ellipta Fluticasone/Vilanterol Brand 133 $85,257
Nucala Mepolizumab Brand 18 $69,575
Spiriva Respimat Tiotropium Bromide Brand 47 $42,625
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 36 $42,573
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 33 $28,899

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$183,416

Of which drugs: $15,332

Medicare patients

643

Average age 78

Services billed

2,500

396 women, 247 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 47%
COPD 44%
Chronic kidney disease 30%
Heart failure 28%
Atrial fibrillation 28%
Diabetes 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 36 36 $10,386
Sarscv2 vac 30mcg trs-suc im 91320 Office 17 17 $2,573
Vaccine for influenza for injection into muscle 90653 Office 30 30 $2,373

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $251
$251 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $189
$189 — —
TEZSPIRE
  • Amgen Inc. $103
  • AstraZeneca Pharmaceuticals LP $77
$179 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $119
$119 12 —
Arikayce
  • Insmed, Inc. $116
$116 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

367 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record